A citation-based method for searching scientific literature

Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin, Markus P Schlaich. Expert Opin Pharmacother 2020
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12
50

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.
Geoffrey D Clarke, Carolina Solis-Herrera, Marjorie Molina-Wilkins, Sandra Martinez, Aurora Merovci, Eugenio Cersosimo, Robert J Chilton, Patricia Iozzo, Amalia Gastaldelli, Muhammad Abdul-Ghani,[...]. Diabetes Care 2017
23
50

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
Peter Gaede, Pernille Vedel, Nicolai Larsen, Gunnar V H Jensen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2003
50


Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Steven E Nissen, Stephen J Nicholls, Kathy Wolski, Richard Nesto, Stuart Kupfer, Alfonso Perez, Horacio Jure, Robert De Larochellière, Cezar S Staniloae, Kreton Mavromatis,[...]. JAMA 2008
622
50


Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
B Wang, J Zhong, H Lin, Z Zhao, Z Yan, H He, Y Ni, D Liu, Z Zhu. Diabetes Obes Metab 2013
119
50

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Ildiko Lingvay, Andrei-Mircea Catarig, Juan P Frias, Harish Kumar, Nanna L Lausvig, Carel W le Roux, Desirée Thielke, Adie Viljoen, Rory J McCrimmon. Lancet Diabetes Endocrinol 2019
44
50

Antihypertensive Drugs and Risk of Cancer: Between Scylla and Charybdis.
Elias Sanidas, Maria Velliou, Dimitrios Papadopoulos, Anastasia Fotsali, Dimitrios Iliopoulos, Marina Mantzourani, Konstantinos Toutouzas, John Barbetseas. Am J Hypertens 2020
4
50

Effects of intensive blood-pressure control in type 2 diabetes mellitus.
William C Cushman, Gregory W Evans, Robert P Byington, David C Goff, Richard H Grimm, Jeffrey A Cutler, Denise G Simons-Morton, Jan N Basile, Marshall A Corson, Jeffrey L Probstfield,[...]. N Engl J Med 2010
50

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Tina Vilsbøll, Mikkel Christensen, Anders E Junker, Filip K Knop, Lise Lotte Gluud. BMJ 2012
491
50

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
50


Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucker. Circulation 2017
208
50



Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.
Atsushi Tanaka, Hisako Yoshida, Mamoru Nanasato, Jun-Ichi Oyama, Tomoko Ishizu, Masayoshi Ajioka, Ryoji Ishiki, Makoto Saito, Yoshisato Shibata, Kohei Kaku,[...]. Int J Cardiol 2018
7
50



Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa, Hidenori Yoshii, Tomio Onuma, Nobuichi Kuribayashi, Takeshi Osonoi, Hideaki Kaneto, Keisuke Kosugi, Yutaka Umayahara,[...]. Diabetes Care 2016
90
50



10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
50

SGLT2 Inhibitors and Mechanisms of Hypertension.
Alexandros Briasoulis, Omar Al Dhaybi, George L Bakris. Curr Cardiol Rep 2018
30
50

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Junichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara, Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi,[...]. J Am Coll Cardiol 2012
206
50

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Yuliya Lytvyn, Petter Bjornstad, Jacob A Udell, Julie A Lovshin, David Z I Cherney. Circulation 2017
180
50


Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study.
Kenta Okada, Satoshi Hoshide, Mitsutoshi Kato, Hiroshi Kanegae, Shun Ishibashi, Kazuomi Kario. J Clin Hypertens (Greenwich) 2021
2
50

Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
Shin Kawasoe, Yukiko Maruguchi, Shoko Kajiya, Hitoshi Uenomachi, Masaaki Miyata, Mariko Kawasoe, Takuro Kubozono, Mitsuru Ohishi. BMC Pharmacol Toxicol 2017
36
50

Benefits and harms of intensive glycemic control in patients with type 2 diabetes.
René Rodriguez-Gutierrez, José Gerardo Gonzalez-Gonzalez, Jorge A Zuñiga-Hernandez, Rozalina G McCoy. BMJ 2019
20
50

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki, Masayuki Kato, Sumie Okahata, Hisayuki Katsuyama, Mikiko Haraguchi, Ai Morita, Ken Ohashi, Kazuo Hara,[...]. Lancet Diabetes Endocrinol 2017
105
50


Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.
Connor A Emdin, Kazem Rahimi, Bruce Neal, Thomas Callender, Vlado Perkovic, Anushka Patel. JAMA 2015
378
50

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
William L Baker, Leo F Buckley, Michael S Kelly, John D Bucheit, Eric D Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L Dixon. J Am Heart Assoc 2017
72
50

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Karen L Margolis, Patrick J O'Connor, Timothy M Morgan, John B Buse, Robert M Cohen, William C Cushman, Jeffrey A Cutler, Gregory W Evans, Hertzel C Gerstein, Richard H Grimm,[...]. Diabetes Care 2014
158
50



24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
Kazuomi Kario, Kenta Okada, Mitsutoshi Kato, Masafumi Nishizawa, Tetsuro Yoshida, Tsuguyoshi Asano, Kazuaki Uchiyama, Yawara Niijima, Tomohiro Katsuya, Hidenori Urata,[...]. Circulation 2018
66
50


Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A Dormandy, Bernard Charbonnel, David J A Eckland, Erland Erdmann, Massimo Massi-Benedetti, Ian K Moules, Allan M Skene, Meng H Tan, Pierre J Lefèbvre, Gordon D Murray,[...]. Lancet 2005
50


Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
722
50

SGLT2i: beyond the glucose-lowering effect.
Lihua Ni, Cheng Yuan, Guopeng Chen, Changjiang Zhang, Xiaoyan Wu. Cardiovasc Diabetol 2020
10
50

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B M Brenner, M E Cooper, D de Zeeuw, W F Keane, W E Mitch, H H Parving, G Remuzzi, S M Snapinn, Z Zhang, S Shahinfar. N Engl J Med 2001
50

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
M Hanefeld, M Cagatay, T Petrowitsch, D Neuser, D Petzinna, M Rupp. Eur Heart J 2004
453
50


How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
279
50

Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life.
Labib Al-Musawe, Carla Torre, Jose Pedro Guerreiro, Antonio Teixeira Rodrigues, Joao Filipe Raposo, Helder Mota-Filipe, Ana Paula Martins. Pharmacol Res Perspect 2020
3
50

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.
Aramesh Saremi, Dawn C Schwenke, Thomas A Buchanan, Howard N Hodis, Wendy J Mack, Maryann Banerji, George A Bray, Stephen C Clement, Robert R Henry, Abbas E Kitabchi,[...]. Arterioscler Thromb Vasc Biol 2013
70
50

Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats.
Tomoko Yoshikawa, Takuya Kishi, Keisuke Shinohara, Ko Takesue, Risa Shibata, Noriyuki Sonoda, Toyoshi Inoguchi, Kenji Sunagawa, Hiroyuki Tsutsui, Yoshitaka Hirooka. Hypertens Res 2017
19
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.